Your browser doesn't support javascript.
loading
Low MBOAT7 expression, a genetic risk for MASH, promotes a profibrotic pathway involving hepatocyte TAZ upregulation.
Moore, Mary P; Wang, Xiaobo; Kennelly, John Paul; Shi, Hongxue; Ishino, Yuki; Kano, Kuniyuki; Aoki, Junken; Cherubini, Alessandro; Ronzoni, Luisa; Guo, Xiuqing; Chalasani, Naga P; Khalid, Shareef; Saleheen, Danish; Mitsche, Matthew A; Rotter, Jerome I; Yates, Katherine P; Valenti, Luca; Kono, Nozomu; Tontonoz, Peter; Tabas, Ira.
Afiliación
  • Moore MP; Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Wang X; Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Kennelly JP; Department of Pathology and Laboratory Medicine, Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Shi H; Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Ishino Y; Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
  • Kano K; Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
  • Aoki J; Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
  • Cherubini A; Precisione Medicine Lab, Biological Resource Center and Department of Transfusion Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
  • Ronzoni L; Precisione Medicine Lab, Biological Resource Center and Department of Transfusion Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
  • Guo X; The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
  • Chalasani NP; Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Khalid S; Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Saleheen D; Center for Non-Communicable Disease, Karachi, Karachi City, Sindh, Pakistan.
  • Mitsche MA; Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Rotter JI; Center for Non-Communicable Disease, Karachi, Karachi City, Sindh, Pakistan.
  • Yates KP; Center for Human Nutrition and Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Valenti L; The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
  • Kono N; Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
  • Tontonoz P; Precisione Medicine Lab, Biological Resource Center and Department of Transfusion Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
  • Tabas I; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.
Hepatology ; 2024 May 22.
Article en En | MEDLINE | ID: mdl-38776184
ABSTRACT
BACKGROUND AND

AIMS:

The common genetic variant rs641738 C>T is a risk factor for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH), including liver fibrosis, and is associated with decreased expression of the phospholipid-remodeling enzyme MBOAT7 (LPIAT1). However, whether restoring MBOAT7 expression in established metabolic dysfunction-associated steatotic liver disease dampens the progression to liver fibrosis and, importantly, the mechanism through which decreased MBOAT7 expression exacerbates MASH fibrosis remain unclear. APPROACH AND

RESULTS:

We first showed that hepatocyte MBOAT7 restoration in mice with diet-induced steatohepatitis slows the progression to liver fibrosis. Conversely, when hepatocyte-MBOAT7 was silenced in mice with established hepatosteatosis, liver fibrosis but not hepatosteatosis was exacerbated. Mechanistic studies revealed that hepatocyte-MBOAT7 restoration in MASH mice lowered hepatocyte-TAZ (WWTR1), which is known to promote MASH fibrosis. Conversely, hepatocyte-MBOAT7 silencing enhanced TAZ upregulation in MASH. Finally, we discovered that changes in hepatocyte phospholipids due to MBOAT7 loss-of-function promote a cholesterol trafficking pathway that upregulates TAZ and the TAZ-induced profibrotic factor Indian hedgehog (IHH). As evidence for relevance in humans, we found that the livers of individuals with MASH carrying the rs641738-T allele had higher hepatocyte nuclear TAZ, indicating higher TAZ activity and increased IHH mRNA.

CONCLUSIONS:

This study provides evidence for a novel mechanism linking MBOAT7-LoF to MASH fibrosis, adds new insight into an established genetic locus for MASH, and, given the druggability of hepatocyte TAZ for MASH fibrosis, suggests a personalized medicine approach for subjects at increased risk for MASH fibrosis due to inheritance of variants that lower MBOAT7.

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Hepatology Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Hepatology Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos